Open Access

miR‑498 inhibits the growth and metastasis of liver cancer by targeting ZEB2

  • Authors:
    • Xu Zhang
    • Xueying Xu
    • Guohong Ge
    • Xueyan Zang
    • Meng Shao
    • Shengqiang Zou
    • Yu Zhang
    • Zheying Mao
    • Jiayin Zhang
    • Fei Mao
    • Hui Qian
    • Wenrong Xu
  • View Affiliations

  • Published online on: December 21, 2018     https://doi.org/10.3892/or.2018.6948
  • Pages: 1638-1648
  • Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

MicroRNAs (miRNAs) play critical roles in the growth, metastasis and therapeutic resistance of liver cancer. Accumulating evidence suggests that miR‑498 is aberrantly expressed in several human malignancies. However, the role and underlying mechanism of miR‑498 in liver cancer remain unclear. In the present study, we investigated the potential roles and clinical value of miR‑498 in liver cancer. We found that the miR‑498 expression level was significantly lower in liver cancer patient tissues than that in healthy control tissues. The expression of miR‑498 was also decreased in liver cancer cell lines compared to that noted in a normal human normal liver cell line. miR‑498 overexpression markedly inhibited liver cancer cell proliferation, migration and invasion. miR‑498 overexpression induced cell cycle arrest and apoptosis while it suppressed epithelial‑mesenchymal transition (EMT) in liver cancer cells. Bioinformatic analysis and luciferase reporter assay further identified zinc finger E‑box binding homeobox 2 (ZEB2) as a novel target of miR‑498. Furthermore, ZEB2 knockdown recapitulated the inhibitory effects of miR‑498 overexpression in liver cancer cells. ZEB2 overexpression rescued the inhibition of liver cancer cell proliferation, migration, and invasion by miR‑498, indicating that ZEB2 acts as a downstream effector of miR‑498 in liver cancer cells. Thus, we demonstrated that miR‑498 suppresses the growth and metastasis of liver cancer cells, partly at least, by directly targeting ZEB2, suggesting that miR‑498 may serve as a potential biomarker for the diagnosis and therapy of liver cancer.
View Figures
View References

Related Articles

Journal Cover

March-2019
Volume 41 Issue 3

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhang X, Xu X, Ge G, Zang X, Shao M, Zou S, Zhang Y, Mao Z, Zhang J, Mao F, Mao F, et al: miR‑498 inhibits the growth and metastasis of liver cancer by targeting ZEB2. Oncol Rep 41: 1638-1648, 2019.
APA
Zhang, X., Xu, X., Ge, G., Zang, X., Shao, M., Zou, S. ... Xu, W. (2019). miR‑498 inhibits the growth and metastasis of liver cancer by targeting ZEB2. Oncology Reports, 41, 1638-1648. https://doi.org/10.3892/or.2018.6948
MLA
Zhang, X., Xu, X., Ge, G., Zang, X., Shao, M., Zou, S., Zhang, Y., Mao, Z., Zhang, J., Mao, F., Qian, H., Xu, W."miR‑498 inhibits the growth and metastasis of liver cancer by targeting ZEB2". Oncology Reports 41.3 (2019): 1638-1648.
Chicago
Zhang, X., Xu, X., Ge, G., Zang, X., Shao, M., Zou, S., Zhang, Y., Mao, Z., Zhang, J., Mao, F., Qian, H., Xu, W."miR‑498 inhibits the growth and metastasis of liver cancer by targeting ZEB2". Oncology Reports 41, no. 3 (2019): 1638-1648. https://doi.org/10.3892/or.2018.6948